How to Enhance Competitiveness of Pharmaceutical Intermediates Enterprises

Pharmaceutical intermediates refer to some chemical raw materials or products used in the pharmaceutical synthesis process. The industry indicates that the pharmaceutical intermediate industry, as an important field of fine chemicals, will have significant development space in the future. 
From the development history of China's pharmaceutical intermediate industry, after nearly 30 years of development, pharmaceutical intermediates have developed from a small branch of the chemical industry to an emerging industry with a value of billions of yuan, and their market competition has become increasingly fierce.
It is understood that in the early stages of the development of the pharmaceutical intermediate industry, due to small investment and high returns, pharmaceutical intermediate enterprises have sprung up like mushrooms, especially in regions such as Zhejiang, Taizhou, and Nanjing that have favorable conditions for the development of pharmaceutical intermediates. 
At present, with the changes in the pharmaceutical market pattern and the limited production of new drugs in the market, the difficulty of developing new products in the pharmaceutical intermediate industry is increasing, and the competition for traditional products is also becoming increasingly fierce. The profits of the pharmaceutical intermediate industry are rapidly declining. Therefore, how to develop pharmaceutical intermediate enterprises has become a difficult problem that must be considered. 
The industry believes that it may be possible to form a competitive advantage for enterprises in terms of technology, influence, transformation, and other aspects, in order to stand out in the market. 
In terms of technology, it mainly refers to improving technology and saving costs. It is reported that the process route of pharmaceutical intermediates is long, there are multiple reaction steps, and the amount of solvent used is large, with great potential for technological improvement. 
In terms of influence, the main focus is to develop our own unique products and enhance industry influence. It is understood that due to the severe homogenization competition in China's pharmaceutical intermediate industry, if enterprises can create their own advantageous products, they will inevitably have a greater advantage in the market. 
In terms of transformation, currently, with stricter environmental protection requirements in China, resources are inclined towards high value-added industries, and with the increase in environmental protection costs, transformation has become a problem that pharmaceutical intermediate enterprises have to consider for sustainable development.